AQSE: EDX
("EDX Medical" or the "Company")
30 September 2024
Annual General Meeting
Result of Annual General Meeting
The Annual General Meeting of EDX Medical Group plc was held at Mezzanine Room, 1 Wimpole Street, Westminster, London, W1G 0AE on 30 September 2024 at 2:00 p.m.
All 11 resolutions put to members were passed on a poll. Resolutions 1 to 9 were passed as ordinary resolutions and resolutions 10 and 11 were passed as special resolutions.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
| Resolution | Votes for | % | Votes against | % | Votes withheld |
| Resolution 1 (Ordinary) To receive the Annual Report and Accounts of the Company for the financial year ended 31 March 2024 together with the Directors' reports and auditor's report on those accounts. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 2 (Ordinary) To receive the Report of the Remuneration Committee for the financial year ended 31 March 2024. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 3 (Ordinary) To re-elect Jason Holt as a director of the Company. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 4 (Ordinary) To re-elect Dr Michael Hudson as a director of the Company. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 5 (Ordinary) To re-elect Professor Sir Christopher Evans OBE as a director of the Company. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 6 (Ordinary) To re-elect Professor Trevor Jones CBE as a director of the Company. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 7 (Ordinary) To re-appoint PKF Littlejohn LLP as auditor of the Company. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 8 (Ordinary) To authorise the Directors to determine the fees payable to the auditor. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 9 (Ordinary) To authorise the directors to allot equity securities pursuant to section 551 of the Companies Act 2006, as set out in the Notice of Meeting. | 189,456,532 | 100.00 | 0 | 0 | 0 |
| Resolution 10 (Special) To disapply statutory pre-emption rights generally, as set out in the Notice of Meeting. | 189,075,584
| 99.84 | 300,000 | 0.16 | 80,948 |
| Resolution 11 (Special) To disapply statutory pre-emption rights pursuant to an acquisition or other capital investment, as set out in the Notice of Meeting. | 189,375,584
| 100.00 | 0 | 0 | 80,948 |
As at 30 September 2024, there were 347,357,576 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.
Contacts
| EDX Medical Group plc |
|
| Dr Mike Hudson (Chief Executive Officer) | +44 (0)7812 345 301 |
|
|
|
| Oberon Capital |
|
| Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) | +44 (0)20 3179 5300 |
|
|
|
|
IFC Advisory (Investor Relations) | |
| Tim Metcalfe | +44 (0)20 3934 6630 |
| Graham Herring | |
|
|
|
| Media House International |
|
| Ramsay Smith
Gary McQueen | +44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk |
Notes for Editors:
About EDX Medical Group
EDX Medical Group Plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases. The company is now listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.
EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiaries "Hutano Diagnostics Ltd", based in Oxford and "Torax Biosciences Ltd" in Ireland which together are pioneering the development of novel point of care tests.
EDX Medical conducts test development and product validation to ISO 13485 and provides testing and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
